Magnesiumsulfaat Teva (Magnesium Sulfate)

Magnesium sulfate provides magnesium ions that act as calcium antagonists at voltage‑gated channels. By limiting calcium entry into cells, it stabilises neuronal membranes, reduces neuromuscular excitability, relaxes smooth muscle, and diminishes vasospasm, which together produce anticonvulsant, vasodilatory and anti‑arrhythmic effects.

The dose of Magnesiumsulfaat Teva is set by the prescribing clinician based on the specific indication, the patient’s weight, renal function, and serum magnesium levels. Dosage regimens are individualized and may be adjusted during therapy to maintain therapeutic concentrations while avoiding toxicity.

Magnesium sulfate is frequently used in obstetric care, particularly for eclampsia and severe preeclampsia, under close medical supervision. While the pregnancy category is listed as unknown, its benefits in these emergencies often outweigh potential risks. Breastfeeding mothers should discuss use with their healthcare provider.

To order Magnesiumsulfaat Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

For obstetric seizures, magnesium sulfate is preferred over agents such as diazepam because it directly addresses the underlying calcium‑mediated excitability and has a well‑established safety profile. In cardiac arrhythmias, it offers a unique mechanism compared with anti‑arrhythmic drugs like lidocaine, making it useful when other agents are contraindicated.

Magnesiumsulfaat Teva should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not store at ambient temperature, as temperature excursions may affect stability.

The product is given by intravenous injection or infusion. Administration may begin with a loading dose followed by a maintenance infusion, with the rate adjusted according to clinical response and serum magnesium monitoring. Infusion should be performed using aseptic technique and appropriate IV equipment.

The most critical adverse events include respiratory depression, cardiac arrest due to severe arrhythmia, and hypermagnesemia leading to loss of deep‑tendon reflexes and muscle weakness. Early detection of these signs through continuous monitoring is essential to prevent life‑threatening complications.

Magnesiumsulfaat Teva is contraindicated in patients with known hypersensitivity to magnesium sulfate, severe renal impairment that prevents magnesium excretion, myasthenia gravis, and certain types of heart block where magnesium may exacerbate conduction abnormalities.